journal article·2021-08-11Open access

Targeting Nanoparticles to Bioengineered Human Vascular Networks

Kathleen Cullion, Laura C. Petishnok, Hyunji Koo, Brendan Harty, Juan M. Melero-Martin, Daniel S. Kohane

Nano Letters· Volume 21· Issue 15

Abstract

Pharmacotherapy of vascular anomalies has limited efficacy and potentially limiting toxicity. Targeted nanoparticle (NP) drug delivery systems have the potential to accumulate within tissues where the vasculature is impaired, potentially leading to high drug levels (increased efficacy) in the diseased tissue and less in off-target sites (less toxicity). Here, we investigate whether NPs can be used to enhance drug delivery to bioengineered human vascular networks (hVNs) that are a model of human vascular anomalies. We demonstrate that intravenously injected phototargeted NPs enhanced accumulation of NPs and the drug within hVNs. With phototargeting we demonstrate 17 times more NP accumulation within hVNs than was detected in hVNs without phototargeting. With phototargeting there was 10-fold more NP accumulation within hVNs than in any other organ. Phototargeting resulted in a 6-fold increase in drug accumulation (doxorubicin) within hVNs in comparison to animals injected with the free drug. Nanoparticulate approaches have the potential to markedly improve drug delivery to vascular anomalies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Vascular Malformations and Hemangiomas · Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory for Biomaterials and Drug Delivery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

Department of Medical Critical Care, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

Department of Anesthesiology, Critical Care, and Pain Management, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

Department of Cardiac Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States

Funding

National Institute of General Medical Sciences · Stuart and Jane Weitzman Family Vascular Anomalies Fund

References (34)

Show source-provided references
1. 10.1001/archderm.144.7.86110.1001/archderm.144.7.861 ↗
2. 10.1016/S0190-9622(97)70284-610.1016/S0190-9622(97)70284-6 ↗
3. 10.1053/j.sempedsurg.2014.06.01510.1053/j.sempedsurg.2014.06.015 ↗
4. 10.1053/j.sempedsurg.2017.09.00710.1053/j.sempedsurg.2017.09.007 ↗
5. 10.1097/00006534-199907000-0000210.1097/00006534-199907000-00002 ↗
6. 10.1111/j.1601-0825.2010.01661.x10.1111/j.1601-0825.2010.01661.x ↗
7. 10.1055/s-0037-160703310.1055/s-0037-1607033 ↗
8. 10.1542/peds.2015-325710.1542/peds.2015-3257 ↗
9. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
10. 10.1021/nl202588210.1021/nl2025882 ↗
11. 10.1038/s41467-019-08690-410.1038/s41467-019-08690-4 ↗
12. 10.1038/natrevmats.2017.2010.1038/natrevmats.2017.20 ↗
13. 10.1021/nl903411s10.1021/nl903411s ↗
14. 10.3390/ph304096110.3390/ph3040961 ↗
15. 10.1126/science.106921010.1126/science.1069210 ↗
16. 10.1016/j.tibtech.2008.04.00910.1016/j.tibtech.2008.04.009 ↗
17. 10.1016/j.addr.2011.03.00410.1016/j.addr.2011.03.004 ↗
18. 10.1172/JCI7600410.1172/JCI76004 ↗
19. 10.1172/JCI3349310.1172/JCI33493 ↗
20. 10.1161/circresaha.108.17859010.1161/circresaha.108.178590 ↗
21. 10.1038/s41551-017-008110.1038/s41551-017-0081 ↗
22. 10.1016/j.biomaterials.2013.05.06010.1016/j.biomaterials.2013.05.060 ↗
23. 10.3791/306510.3791/3065 ↗
24. 10.1016/j.tips.2017.01.00310.1016/j.tips.2017.01.003 ↗
25. 10.1021/bi700280e10.1021/bi700280e ↗
26. 10.1246/bcsj.2012031410.1246/bcsj.20120314 ↗
27. 10.1073/pnas.131533611010.1073/pnas.1315336110 ↗
28. 10.1016/j.jphotobiol.2017.03.02410.1016/j.jphotobiol.2017.03.024 ↗
29. 10.1007/978-1-4757-4627-3_1110.1007/978-1-4757-4627-3_11 ↗
30. 10.1007/s10103-017-2317-410.1007/s10103-017-2317-4 ↗
31. 10.1088/0031-9155/35/9/01010.1088/0031-9155/35/9/010 ↗
32. 10.1038/s41551-017-0117-610.1038/s41551-017-0117-6 ↗
33. 10.3389/fphar.2018.0132910.3389/fphar.2018.01329 ↗
34. 10.3389/fbioe.2019.0011310.3389/fbioe.2019.00113 ↗